In a bold stride toward strengthening its grip on the immunology and rare disease market, French pharmaceutical titan Sanofi SA said Monday it has reached an agreement to acquire U.S.-based Blueprint Medicines Corp. for up to $9.5 billion — a deal that’s electrifying the biotech landscape.
The agreement, structured with surgical precision, includes a $129-per-share offer, representing a 27% premium over Blueprint’s last traded price of $101.35. That alone values the Nasdaq-listed company at $9.1 billion, but the final sum could swell with an additional $400 million in milestone-based payouts linked to Blueprint’s experimental immunology drug, Blu-808.
Deal Financed by Cash, Debt — and Strategic Firepower
Sanofi plans to finance the buyout through a mix of cash reserves and new debt, reaffirming its aggressive growth strategy in the highly competitive pharmaceutical sector. The Paris-based firm expects the transaction to close in Q3 2025, pending customary regulatory and shareholder approvals.
Weil Gotshal & Manges LLP is advising Sanofi, with a high-powered team out of New York led by Michael J. Aiello and Sachin Kohli. Blueprint is represented by Goodwin Procter LLP, including a roster of top-tier legal talent: Stuart Cable, Lisa Haddad, Kingsley Taft, and additional partners across healthcare and regulatory law.
